Furthermore, a study demonstrated that ABT737, a BCL2 inhibitor, reduces the cisplatin resistance of SKOV3 ovarian cancer cells by modulating Ca2+ signaling159,160. This evidence concerns the gene BCL2 and ovarian cancer.